Brief: Galmed Announces Positive Results Of Phase 1 Study Of AMILO-5MER

Eocene

10/01/2022 12:36

Jan 10 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED ANNOUNCES POSITIVE RESULTS OF PHASE 1 STUDY OF AMILO-5MER
    * GALMED PHARMACEUTICALS LTD - SINGLE AND MULTIPLE ESCALATING DOSE RESULTS
WITH
EXCELLENT SAFETY PROFILE AND TOLERABILITY
    * GALMED PHARMACEUTICALS LTD - SUBMISSION OF AN IND FOR MILD TO MODERATE
ULCERATIVE COLITIS IS PLANNED IN 2022
    * GALMED PHARMACEUTICALS LTD - ALL DOSES OF AMILO-5MER WERE WELL TOLERATED
WITH NO
CLINICALLY SIGNIFICANT ADVERSE EVENTS

Source text for Eikon:  ID:nPn9wmD0ga 
Further company coverage:  GLMD.O